D8.2 Administration and Management: The TSRI Center will be administered by the PI in consultation with the Center Screening Committee. The functional cores (Assay Implementation, uHTS Implementation, Informatics, PK, Chemistry and QA) will meet on a monthly basis to set goals and metrics towards those interim goals, as well as monitor progress towards the global Specific Aims with their timed milestones. Variances of >1 Quarter from the planned global milestones will be flagged by the PI and brought to the attention of the CSC. Remedial steps will be taken in real time to solve the specific problems. Should the PI, in consultation with the CSC, identify variances that, after remedial steps have been taken, still impact on scope or timeliness of deliverables, the PI will draw this to the attention of NIH staff where appropriate and seek guidance. In addition to the successful implementation ahead of time and on budget of the MLSCN Center and chairing the MLSCN Steering Group, the PI had significant therapeutic area head level industrial experience at Merck. It is well within his capabilities to define key Center problems and lead them to resolution at the appropriate level within the Center or the NIH Project Team. Integration of Assay Development, Adaptation and uHTS implementation is managed by the monthly meeting of the Screening Coordination Committee (SCC).

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BCMB-D)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Penas, Clara; Ramachandran, Vimal; Simanski, Scott et al. (2014) Casein kinase 1?-dependent Wee1 protein degradation. J Biol Chem 289:18893-903
Chang, Mi Ra; Lyda, Brent; Kamenecka, Theodore M et al. (2014) Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor ? is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol 66:579-88
Yan, Fei; Yu, Yang; Chow, Dar-Chone et al. (2014) Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One 9:e95243
Sarkisyan, Gor; Gay, Laurie J; Nguyen, Nhan et al. (2014) Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth. Am J Physiol Cell Physiol 307:C14-24
Lewallen, Daniel M; Bicker, Kevin L; Madoux, Franck et al. (2014) A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol 9:913-21
Lewallen, Daniel M; Sreelatha, Anju; Dharmarajan, Venkatasubramanian et al. (2014) Inhibiting AMPylation: a novel screen to identify the first small molecule inhibitors of protein AMPylation. ACS Chem Biol 9:433-42
Gentry, Patrick R; Kokubo, Masaya; Bridges, Thomas M et al. (2014) Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). J Med Chem 57:7804-10
Yun, Bogeon; Lee, HeeJung; Ghosh, Moumita et al. (2014) Serine hydrolase inhibitors block necrotic cell death by preventing calcium overload of the mitochondria and permeability transition pore formation. J Biol Chem 289:1491-504
Niphakis, Micah J; Cravatt, Benjamin F (2014) Enzyme inhibitor discovery by activity-based protein profiling. Annu Rev Biochem 83:341-77
Dreyton, Christina J; Anderson, Erin D; Subramanian, Venkataraman et al. (2014) Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem 22:1362-9

Showing the most recent 10 out of 80 publications